Dezapelisib

Drug Profile

Dezapelisib

Alternative Names: INCB-40093; INCB040093

Latest Information Update: 12 Feb 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics; Purines; Pyrimidinones; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Jan 2017 Incyte corporation completes a phase-II trial in Hodgkin's disease (Monotherapy, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT02456675)
  • 12 Dec 2016 Chemical structure information added
  • 11 Jan 2016 Discontinued - Phase-I/II for Hodgkin's disease (Combination therapy, Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top